Skip to Content

Join the 'Gammagard S / D' group to help and get support from people like you.

Gammagard S / D News

Densensitization Procedure Helps Hard-to-Match Kidney Recipients

Posted 27 Jul 2011 by Drugs.com

WEDNESDAY, July 27 – A combination therapy that "desensitizes" kidney transplant recipients could help hard-to-match patients find a needed kidney faster. The desensitization procedure combines the use of plasmapheresis – a machine that filters the blood plasma to remove antibodies – and low-doses of a medication called intravenous immune globulin (IVIG). The combination of these therapies improves survival rates dramatically. Eight years after receiving a transplant, survival rates were 81 percent for those who received the treatment compared to just 31 percent for people who had to stay on dialysis, new research found. "This is a huge unmet problem. There are probably as many as 30,000 people who have been exposed to foreign tissue waiting for a kidney. They're really hard to match," explained study author Dr. Robert Montgomery, director of the comprehensive transplant program at ... Read more

Related support groups: Renal Transplant, Gammagard, Gamunex, Privigen, Immune Globulin Intravenous, Sandoglobulin, Carimune, Octagam, Gamimune N 5%, Gammaplex, Polygam S/D, Gammagard S/D, Flebogamma, Venoglobulin-S 5%, Gamimune N 10%, Panglobulin NF, Gammar-P IV, Carimune NF, Venoglobulin-S 10%, Iveegam En

Baxter Announces FDA Approval of Subcutaneous Route of Administration for Gammagard Liquid for Patients with Primary Immunodeficiency

Posted 25 Jul 2011 by Drugs.com

DEERFIELD, Ill.--(BUSINESS WIRE)--Jul 25, 2011 - Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous administration of Gammagard Liquid 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency (PI). The approval of this new route of administration will allow physicians and PI patients to work together to determine which route of administration of Gammagard Liquid is most appropriate. Subcutaneous use of Gammagard Liquid allows patients to self-administer their therapy at home on a weekly basis. "The FDA approval of a subcutaneous route of administration for Gammagard Liquid offers PI patients the option to administer Gammagard Liquid either intravenously or subcutaneously, depending on their individual needs," said Richard Schiff, M.D., Ph.D., medical director for Baxter's gammaglobulin trials. ... Read more

Related support groups: Primary Immunodeficiency Syndrome, Gammagard, Gammagard S/D

Ask a Question

Further Information

Related Condition Support Groups

Chronic Lymphocytic Leukemia (CLL), Idiopathic (Immune) Thrombocytopenic Purpura, Autoimmune Neutropenia, Bone Marrow Transplantation, Primary Immunodeficiency Syndrome, Evan's Syndrome, Polymyositis / Dermatomyositis, HIV Infection, Kawasaki Disease

Gammagard S / D Patient Information at Drugs.com